Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Srinivas R. Valluri"'
Autor:
James H. Stark, Xiuyan Li, Ji Chun Zhang, Leah Burn, Srinivas R. Valluri, Jiaxin Liang, Kaijie Pan, Mark A. Fletcher, Raphael Simon, Luis Jodar, Bradford D. Gessner
Publikováno v:
Emerging Infectious Diseases, Vol 28, Iss 12, Pp 2389-2397 (2022)
Since its initial identification in 1986, Lyme disease has been clinically diagnosed in 29 provinces in China; however, national incidence data are lacking. To summarize Lyme disease seropositivity data among persons across China, we conducted a syst
Externí odkaz:
https://doaj.org/article/9fa2104233f646bba8aba0302d97cae7
Autor:
Sara Y, Tartof, Jeff M, Slezak, Laura, Puzniak, Vennis, Hong, Timothy B, Frankland, Fagen, Xie, Bradley K, Ackerson, Srinivas R, Valluri, Luis, Jodar, John M, McLaughlin
Publikováno v:
The Lancet Respiratory Medicine. 11:176-187
The SARS-CoV-2 omicron (B.1.1.529 BA.1) lineage was first detected in November, 2021, and is associated with reduced vaccine effectiveness. By March, 2022, BA.1 had been replaced by sub-lineage BA.2 in the USA. As new variants evolve, vaccine perform
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d012b428ef296090d086519eadd51c8
https://doi.org/10.1016/s2213-2600(22)00354-x
https://doi.org/10.1016/s2213-2600(22)00354-x
Autor:
Sara Y, Tartof, Jeff M, Slezak, Laura, Puzniak, Vennis, Hong, Fagen, Xie, Bradley K, Ackerson, Srinivas R, Valluri, Luis, Jodar, John M, McLaughlin
Publikováno v:
The Lancet Respiratory Medicine. 10:689-699
The duration of protection against the omicron (B.1.1.529) variant for current COVID-19 vaccines is not well characterised. Vaccine-specific estimates are especially needed. We aimed to evaluate the effectiveness and durability of two and three doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3417fcf5d8515881827a38d21a872b07
https://doi.org/10.1016/s2213-2600(22)00101-1
https://doi.org/10.1016/s2213-2600(22)00101-1
Autor:
Catherine Hyams, Robert Challen, Elizabeth Begier, Jo Southern, Jade King, Anna Morley, Zsuzsa Szasz-Benczur, Maria Garcia Gonzalez, Jane Kinney, James Campling, Sharon Gray, Jennifer Oliver, Robin Hubler, Srinivas R. Valluri, Andrew Vyse, John M. McLaughlin, Gillian Ellsbury, Nick Maskell, Bradford Gessner, Leon Danon, Adam Finn
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db74f962b2314876d2a0d76f38a60112
https://doi.org/10.2139/ssrn.4087373
https://doi.org/10.2139/ssrn.4087373
Autor:
Sara Y. Tartof, Jeff M. Slezak, Laura Puzniak, Vennis Hong, Fagen Xie, Bradley K. Ackerson, Srinivas R. Valluri, Luis Jodar, John M. McLaughlin
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b6d941912e54c787a38a904a300d182
https://doi.org/10.2139/ssrn.4011905
https://doi.org/10.2139/ssrn.4011905
Autor:
Sara Y. Tartof, Jeff M. Slezak, Laura Puzniak, Vennis Hong, Fagen Xie, Bradley K. Ackerson, Srinivas R. Valluri, Luis Jodar, John M. McLaughlin
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6af4591ec83b5843f8fd1b6aeddf57d
https://doi.org/10.2139/ssrn.4150500
https://doi.org/10.2139/ssrn.4150500
Autor:
Sara Y, Tartof, Jeff M, Slezak, Laura, Puzniak, Vennis, Hong, Fagen, Xie, Bradley K, Ackerson, Srinivas R, Valluri, Luis, Jodar, John M, McLaughlin
Publikováno v:
The Lancet Respiratory Medicine. 10:e61-e62
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c989566b871364545e88c5ea7e4e4d52
https://doi.org/10.1016/s2213-2600(22)00170-9
https://doi.org/10.1016/s2213-2600(22)00170-9
Autor:
Sara Y, Tartof, Timothy B, Frankland, Jeff M, Slezak, Laura, Puzniak, Vennis, Hong, Fagen, Xie, Bradley K, Ackerson, Srinivas R, Valluri, Luis, Jodar, John M, McLaughlin
Publikováno v:
JAMA Network Open. 5:e2225162
Data about the duration of protection of 2 and 3 doses of BNT162b2 in children and adolescents are needed to help inform recommendations for boosters in this age group.To evaluate vaccine effectiveness (VE) and durability associated with 2 doses of B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4309a36f49f31348645d415414d10d2d
https://doi.org/10.1001/jamanetworkopen.2022.25162
https://doi.org/10.1001/jamanetworkopen.2022.25162
Autor:
Sara Y. Tartof, Jeff M. Slezak, Laura Puzniak, Vennis Hong, Timothy B. Frankland, Bradley K. Ackerson, Harpreet S. Takhar, Oluwaseye A. Ogun, Sarah R. Simmons, Joann M. Zamparo, Sharon Gray, Srinivas R. Valluri, Kaije Pan, Luis Jodar, John M. McLaughlin
Publikováno v:
The Lancet Regional Health - Americas. 9:100198
Globally, recommendations are expanding for third (booster) doses of BNT162b2 (Pfizer-BioNTech). In the United States, as of November 19, 2021, boosters were recommended for all adults aged 18 years and older. We evaluated the effectiveness of a thir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::889a7f18cae67eea41e37b66e4b657cf
https://doi.org/10.1016/j.lana.2022.100198
https://doi.org/10.1016/j.lana.2022.100198
Autor:
Jayvant, Heera, Srinivas R, Valluri, Charles, Craig, Annie, Fang, Neal, Thomas, Ralph D, Meyer, Marilyn E, Lewis, Elna, van der Ryst, James, Demarest
Publikováno v:
The new microbiologica. 42(2)
Maraviroc (MVC, a CCR5 antagonist) is only fully active against CCR5 tropic [R5] HIV-1, and tropism testing is required prior to initiating treatment. The MODERN study prospectively compared genotypic (GTT) and phenotypic (Trofile®) tropism testing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d6fdace2c3dc7f3ba5943c46e92f2a48
https://pubmed.ncbi.nlm.nih.gov/31034084
https://pubmed.ncbi.nlm.nih.gov/31034084